23 podcast episode, Brecka pressed Makary on how FDA policies might evolve with regard to a wide range of unapproved treatments and devices, including a blood filter, stem cells for type 1 diabetes, and peptides like BPC-157
hdl:10665/42716
809 CsA@ApoFn, which encapsulates CsA with apoferritin (ApoFn), enters cardiomyocytes through TFR1-mediated endocytosis
Results tend to appear faster and more dramatically than topical application
[2] [3] NAD+ is continuously recycled within cells as it is interconverted to and from its various forms through salvage pathways
When looking to buy BPC-157, injections (whether subcutaneous or intramuscular) offer a more focused strategy, particularly beneficial for conditions such as musculoskeletal injuries, granting direct entry to the impacted tissues